+$0.50 to $10.15 EOM

+$0.81 to $9.65 today, looks like we will get to test $10 soon. EOM

Picked up a few shares in the mid 7's myself today EOM

+$0.72 to $9.20 EOM

Onyx Pharma Soars On Positive Liver-Cancer Drug Trial Result
Dow Jones Newswires - February 12, 2007 12:08 PM ET

By Henry Sanderson

Of DOW JONES NEWSWIRES



NEW YORK (Dow Jones)--Shares of Onyx Pharmaceuticals Inc. (ONXX) rose as much as 62% Monday after it and partner Bayer AG (BAY) reported a positive outcome for the final trial of a treatment for advanced liver cancer, paving the way for approval of the drug.

The companies plan to file for approval for the treatment, Nexavar, based on the positive data in the U.S., Europe and elsewhere.

Hollings Renton, chief executive of Onyx, said Monday during a CNBC interview that the company was meeting with regulators and proceeding to file a supplementary application for approval of the drug "as quickly as we can."

Nexavar is currently approved for kidney cancer in nearly 50 countries.

Shares of Onyx were recently up $6.99, or 57%, at $19.25, with more than five times the average daily volume of shares already traded.

U.S.-listed shares of Germany's Bayer were up 0.2% at $57.92.

Merrill Lynch analyst Eric Ende said he estimates the drug could be worth around $200 million worldwide, and between $75 million to $100 million in the U.S.

The companies said the trial met its primary endpoint of "overall survival" in patients receiving Nexavar tablets compared to placebo, but didn't give further details.

Release of this data will be saved for a June meeting of the American Society of Clinical Oncology, known as ASCO, the companies said.

Prudential Equity Group analyst Jason Zhang wrote in a research note that without specific data from the trial it is difficult to predict chances for approval.

He noted, however, that earlier Phase II data showed that overall survival of 9.5 months was better than most chemotherapy drugs.

Primary liver cancer, is a "significant unmet medical need with no approved therapies in the U.S.," Banc of America Securities analyst David Witzke wrote in a research report, adding it represents a greater opportunity for Nexavar than kidney cancer.



-By Henry Sanderson, Dow Jones Newswires; 201-938-4046; henry.sanderson@dowjones.com



> Dow Jones Newswires

02-12-07 0953ET

Dr. Sunil Chada, PhD., Introgen's associate vice president of Research and Clinical Development, said, "INGN 241 functions to block angiogenesis by inhibiting production of VEGF -- a critical protein in tumor angiogenesis. In contrast, Avastin blocks binding of VEGF to its receptor. Thus combining these two agents with distinct but complementary anti-angiogenic mechanisms provides synergistic anti-tumor effects and completely eradicates tumors resulting in dramatic cures and improvement in survival."

This statement is from Jan 24th news. Sure sounds to me like they have the cure for... What is that worth?

Volume and price up this morning. Tension building up on the 5 million short.

I guess the market likes the report +$1.10 to $7.70.

#1 gainer on the Amex today.

Anti-HIV Predictive Models Released by Simulations Plus

Jan 31, 2007 14:07:28 (ET)


LANCASTER, Calif., Jan 31, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (SLP, Trade ), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has released two new powerful predictive models that extend and enhance the capabilities of its class-leading ADMET Predictor software product. ADMET is a pharmaceutical industry acronym meaning Absorption, Distribution, Metabolism, Excretion and Toxicity.

Dr. Robert Fraczkiewicz, ADMET Predictor software product manager and team leader for ADMET Cheminformatics, said: "The new models we released today predict the ability of potential new drug molecules to interfere with the replication of the human immunodeficiency virus Type 1 (HIV-1) by interfering with an essential enzyme known as HIV integrase. This enzyme serves to catalyze the insertion of the viral genome into the host cell chromosome. Because integrase has no human counterpart, it is an attractive target for potential new drugs to combat HIV-1. Our proprietary model-building capabilities within ADMET Predictor have enabled us to build a predictive capability that allows pharmaceutical scientists to assess the likelihood of new chemical entities to interfere with the replication of the HIV virus in two ways: one model predicts the ability of a potential new drug compound to interfere with a process called strand transfer, while the second model predicts the ability of a potential new drug compound to interfere with what is known as 3'-processing. Both of these steps are essential for the virus to replicate and survive. To our knowledge, these are the most accurate models available for the prediction of these two activities."

Ron Creeley, vice president of marketing and sales of Simulations Plus, added: "These new models are intended to help address a critical area of health care worldwide - the spread of HIV and AIDS. Combined with the numerous other predictive models in ADMET Predictor, chemists can quickly assess how changes to a lead compound not only affect the ability of their new compound to interfere with HIV-1, but also whether those changes provide acceptable properties without resulting in certain toxic side effects. All licensed users of ADMET Predictor will receive the new models as a no-cost extension to their current licenses."

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc. is headquartered in Southern California. For more information, visit our Web site at www.simulations-plus.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: continued acceptance and licensing of ADMET Predictor and the other products of the Company, the ability of the Company to maintain its competitive advantage, the general economics of the pharmaceutical and assistive technology industries, the ability of the Company to attract and retain sufficient scientific and technical staff to sustain its R&D and customer support functions, the continued high renewal rate for the Company's software licenses, and a sustainable market. Further information on the Company's risk factors is contained in the Company's quarterly and annual reports as filed with the Securities and Exchange Commission.

SOURCE: Simulations Plus, Inc.


Simulations Plus, Inc.
Investor Relations
Ms. Renee Bouche, 661-723-7723
info@simulations-plus.com

dickmilde, thank you for your comments. EOM

dickmilde... In your opinion, if they have a million in additional revenue for the first 1 1/2 quarters, do you think that would drop straight to the bottom line as profit?

Thanks...

SLP had a conference call yesterday, here are the highlights.

http://www.sec.gov/Archives/edgar/data/1023459/000101968707000091/simulations_8k-ex9902.htm

Profits are increasing rapidly.

O.k., I found it. Pretty impressive...

http://www.sec.gov/Archives/edgar/data/1023459/000101968707000091/simulations_8k-ex9902.htm

600,000 shares of LRG so any good news is good news. EOM

+$0.72 to $7.47...Must have been a pretty good conference call yesterday. I intended on listening in but had something come up and couldn't. Anybody have highlights?

Combination of Introgen's Nanoparticles Demonstrate Increased Efficacy in the Treatment of Metastatic Lung Cancer

Jan 16, 2007 11:00:06 (ET)


AUSTIN, Texas, Jan 16, 2007 (BUSINESS WIRE) -- Two powerful tumor suppressor genes, p53 and FUS1, administered intravenously in nanoparticle formulations were capable of significantly shrinking metastatic tumors in models of human lung cancer, according to investigators at The University of Texas M. D. Anderson Cancer Center. Molecular cancer therapies using these genes, p53 and FUS1, are in clinical-stage development by Introgen Therapeutics (INGN, Trade ). The technologies are included in a broad portfolio of intellectual properties licensed exclusively to Introgen from M. D. Anderson Cancer Center and other institutions.

The study, published in the January 15 issue of the journal Cancer Research, found that each of the nanoparticle tumor suppressors was effective therapy but more powerful results were observed when the treatments were combined. Systemic therapy with combined p53 and FUS1 nanoparticles in disseminated, metastatic lung cancers decreased the number of human lung tumors by 75 percent and cut their size by 80 percent. The studies also showed that the nanoparticle treatments had no demonstrable adverse effects on normal cells.

Abnormalities of the p53 and FUS1 tumor suppressors are among the most common molecular defects found in human cancers. The mechanism of the increased activity of the combined therapy was determined. The restoration of FUS1 function prevented the breakdown of the administered p53 resulting in its increased ability to destroy tumor cells.

This novel treatment strategy - the first time that two functional tumor suppressor genes have been used in a nanoparticle treatment - may offer a promising clinical treatment for lung and other cancers, according to lead author Lin Ji, Ph.D., assistant professor in the Department of Thoracic & Cardiovascular Surgery research at M. D. Anderson.

Robert E. Sobol, M.D., Introgen's senior vice president, Medical and Scientific Affairs stated, "These results further support our continued clinical development of p53 and FUS1 tumor suppressor therapies. These nanoparticle formulations facilitate treatment of disseminated cancers and validate the important concept of combining tumor suppressors selected to work synergistically in killing cancer cells while leaving normal cells unharmed."

In this study, the researchers tested the combined FUS1/p53 nanoparticles against four different human lung cancers as well as in normal non-cancerous cells. The treatment dramatically inhibited tumor cell growth in all four lung cancers tested, they said. It also induced cell death in the tumors, likely through the activation of p53 and FUS1 mediated gene functions that resulted in the killing of cancer cells but not normal cells.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its clinical development program with p53 and FUS1 for treatment of cancer or other diseases. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: M. D. Anderson Cancer Center also issued a news release about this publication. It may be found at www.mdanderson.org .

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com .

SOURCE: Introgen Therapeutics, Inc.

Looking strong today + $0.38 to $5.03 so far.

Simulations Plus Announces First Quarter Fiscal Year 2007 Earnings Conference Call
BusinessWire - January 10, 2007 9:15 AM ET

Simulations Plus, Inc. (AMEX:SLP), a leading provider of ADMET absorption simulation and structure-to-property prediction software for pharmaceutical discovery and development, will hold a conference call to discuss its first quarter fiscal year 2007 (ended November 30, 2006) results on Tuesday, January 16, at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time).

Shareholders and interested parties may join the conference call by dialing toll-free (800) 967-7184, and referencing either 'Simulations Plus First Quarter Fiscal Year 2007 Results' or confirmation code 9150524. The conference call may also be accessed from outside the United States by dialing (719) 457-2633. Please dial-in five to ten minutes prior to the scheduled start time. Playback should be available on our web site within 72 hours.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "Normally we would do a conference call at the end of the second quarter and then when the 10K is released. But with the increased interest and activity in our stock lately, we feel that it is appropriate to add a conference call to discuss the first quarter results, which we expect to be filed by January 16th."

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc. is headquartered in Southern California. For more information, visit our Web site at www.simulations-plus.com.

SOURCE: Simulations Plus, Inc.

Simulations Plus, Inc.
Investor Relations
Ms. Renee Bouche, 661-723-7723
info@simulations-plus.com

SimulationsPlus Sees Improved 2Q Vs Last Yr >SLP Dow Jones Newswires

Simulations Plus Receives Large Multi-Year Pharmaceutical Software License
BusinessWire - December 14, 2006 3:18 PM ET

Simulations Plus, Inc. (AMEX:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that F. Hoffmann-LaRoche ("Roche") (NYSE:RHHBY) has renewed and expanded its global licenses for Simulations Plus software for another two years.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: "Roche's scientists have been among our longest-standing users and have provided numerous suggestions for improving especially GastroPlus(TM) over the years. Our software has become a significant component of Roche's research methodologies and its use continues growing within the company's community of world-class scientists. Because of this, this new contract is larger than before in both number of software licenses and sales revenues per year."

Momoko Beran, chief financial officer for Simulations Plus, added: "As we announced earlier, multi-year licenses are now being unlocked, and the revenues are being recognized, one year at a time to avoid the undulating revenues and earnings that we experienced in the past when we recognized revenues from multi-year licenses up-front. This new license is a renewal of a previous multi-year license for which the revenues had been booked up front, so no revenues were booked last year for this customer. That means that we expect the second quarter for this fiscal year will be improved over last year's record second quarter by the additional revenues from this order."

The Company's second fiscal quarter will end on February 28.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California and trades on the AMEX under the symbol "SLP." For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

SOURCE: Simulations Plus, Inc.

Simulations Plus
Investor Relations
Renee Bouche, 661-723-7723
info@simulations-plus.com

Simulations Plus Receives Another Large Pharmaceutical Software License Renewal
BusinessWire - December 21, 2006 3:36 PM ET


Simulations Plus, Inc. (AMEX:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from a top five pharmaceutical company for renewed and expanded global licenses for Simulations Plus software.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: "Like our announcement of the renewal last week, this company's scientists have also been among our longest-standing users and have provided numerous suggestions for improving GastroPlus(TM) over the years. Feedback from our users at this customer's research sites indicates that GastroPlus is playing an increasing role in studies during preclinical development, including helping to determine first dose amounts in human - a critical decision prior to conducting Phase I trials."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: "This new license is a renewal of the global license that slipped from the first quarter to the second quarter last year. Because this renewal again comes in the second quarter, it adds to the large order announced last week which means that pharmaceutical software and services revenues for the second quarter of this fiscal year already significantly exceed last year's record second quarter. I would also like to take this opportunity to wish all of our shareholders a very happy and safe holiday season and new year."

The Company's second fiscal quarter will end on February 28.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California and trades on the AMEX under the symbol "SLP." For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

SOURCE: Simulations Plus, Inc.

Simulations Plus, Inc.
Investor Relations
Ms. Renee Bouche, 661-723-7723
info@simulations-plus.com

U.S. FDA Licenses GastroPlus(TM)

Jan 9, 2007 09:15:11 (ET)


LANCASTER, Calif., Jan 09, 2007 (BUSINESS WIRE) -- Simulations Plus, Inc. (SLP, Trade ), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration to license the Company's GastroPlus(TM) simulation software.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: "We're very pleased that the FDA has licensed GastroPlus for use in its internal research. We believe this license is an indication of the utility of GastroPlus as one of the tools the FDA and industry use in various research projects."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "We recently worked on a few projects with FDA scientists using GastroPlus that resulted in joint publication of scientific posters. The FDA's position in advocating for better simulation and modeling tools was expressed in its well-known white paper entitled "Innovation or Stagnation, Challenge and Opportunity on the Critical Path to New Medical Products" released in March 2004. In it, the FDA stated: '. . . a new product development toolkit - containing powerful new . . . methods such as . . . computer-based predictive models . . . is urgently needed. . . . The medical product development process is no longer able to keep pace with basic scientific innovation. Only a concerted effort to apply the new biomedical science to medical product development will succeed in modernizing the critical path.'"

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California and trades on the AMEX under the symbol "SLP." For more information, visit our Web site at www.simulations-plus.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

SOURCE: Simulations Plus, Inc.


Simulations Plus, Inc.
Ms. Renee Bouche, Investor Relations, 661-723-7723
info@simulations-plus.com

Trading Halt - Columbia Metals Corp. Ltd - COL


VANCOUVER, Jan. 11 /CNW/ - The following issues have been halted by Market Regulation Services (RS):

Issuer Name: Columbia Metals Corp. Ltd

TSX-V Ticker Symbol: COL

Time of Halt: 9:27 EST

Reason for Halt: Request of company pending news

Doubloon, appears to be a good business plan. Any ideas when they will begin reporting profits, etc. Any plans to move off of the pinks?

Thanks...

Introgen's INGN 241 Shows Synergy With Heat Shock Protein Inhibitors

Jan 9, 2007 13:00:00 (ET)


AUSTIN, Texas, Jan 09, 2007 /PRNewswire-FirstCall via COMTEX/ -- Results from a new Introgen Therapeutics, Inc. (INGN, Trade ) study have demonstrated that its INGN 241 cancer therapy induces human lung cancer cells to undergo apoptosis, or programmed cell death, via newly discovered mechanisms of action. The preclinical study announced today documented the synergistic action of INGN 241 and a promising new class of tumor-targeted drugs called heat shock protein 90 (Hsp90) inhibitors. In the study, the combination of INGN 241 and two Hsp90 inhibitors resulted in the enhancement of cell death in lung cancer cells. Introgen has studied the various ways in which INGN 241 may be used in the treatment of cancer and this combination treatment offers promise for improving efficacy using low toxicity drugs for lung cancer.

The study was performed by Dr. Abujiang Pataer, M.D., PhD, assistant professor, and Dr. Stephen Swisher, professor, both in the Department of Thoracic and Cardiovascular Surgery at The University of Texas M. D. Anderson Cancer Center, in collaboration with Introgen scientists. The study is published in the current issue of Cancer Gene Therapy.

Dr. Sunil Chada, Introgen's associate vice president of Clinical Research and Development said, "The Hsp90 inhibitors are a promising new class of drugs that have recently entered clinical trials. The synergistic results found by the combination of INGN 241 and this class of tumor-targeted drugs are encouraging and warrant further investigation."

In the study, the Hsp90 inhibitors geldanamycin (GA) and 17-AAG (17-N- Allylamino-17-Demethoxygeldanamycin) were combined with INGN 241 and killing of lung tumor cells evaluated. The combination treatment proved to be highly synergistic as significant increased tumor cell killing was observed when INGN 241 was added to GA or 17-AAG treatment. Additional studies were performed to evaluate the ability of tumor cells to migrate and metastasize; the combination treatment dramatically inhibited tumor cell movement, suggesting an anti-metastatic effect.

About Introgen Therapeutics, Inc.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Introgen holds a licensing agreement with M. D. Anderson Cancer Center to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M. D. Anderson's conflict of interest policies.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its INGN 241 clinical development program for treatment of cancer either alone or in combination with other classes of drugs, such as hsp90 inhibitors. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: http://www.introgen.com .


Contact:
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
Email: c.burke@introgen.com

Introgen's INGN 241 Shows Synergy With Heat Shock Protein Inhibitors

Jan 9, 2007 13:00:00 (ET)


AUSTIN, Texas, Jan 09, 2007 /PRNewswire-FirstCall via COMTEX/ -- Results from a new Introgen Therapeutics, Inc. (INGN, Trade ) study have demonstrated that its INGN 241 cancer therapy induces human lung cancer cells to undergo apoptosis, or programmed cell death, via newly discovered mechanisms of action. The preclinical study announced today documented the synergistic action of INGN 241 and a promising new class of tumor-targeted drugs called heat shock protein 90 (Hsp90) inhibitors. In the study, the combination of INGN 241 and two Hsp90 inhibitors resulted in the enhancement of cell death in lung cancer cells. Introgen has studied the various ways in which INGN 241 may be used in the treatment of cancer and this combination treatment offers promise for improving efficacy using low toxicity drugs for lung cancer.

The study was performed by Dr. Abujiang Pataer, M.D., PhD, assistant professor, and Dr. Stephen Swisher, professor, both in the Department of Thoracic and Cardiovascular Surgery at The University of Texas M. D. Anderson Cancer Center, in collaboration with Introgen scientists. The study is published in the current issue of Cancer Gene Therapy.

Dr. Sunil Chada, Introgen's associate vice president of Clinical Research and Development said, "The Hsp90 inhibitors are a promising new class of drugs that have recently entered clinical trials. The synergistic results found by the combination of INGN 241 and this class of tumor-targeted drugs are encouraging and warrant further investigation."

In the study, the Hsp90 inhibitors geldanamycin (GA) and 17-AAG (17-N- Allylamino-17-Demethoxygeldanamycin) were combined with INGN 241 and killing of lung tumor cells evaluated. The combination treatment proved to be highly synergistic as significant increased tumor cell killing was observed when INGN 241 was added to GA or 17-AAG treatment. Additional studies were performed to evaluate the ability of tumor cells to migrate and metastasize; the combination treatment dramatically inhibited tumor cell movement, suggesting an anti-metastatic effect.

About Introgen Therapeutics, Inc.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Introgen holds a licensing agreement with M. D. Anderson Cancer Center to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M. D. Anderson's conflict of interest policies.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its INGN 241 clinical development program for treatment of cancer either alone or in combination with other classes of drugs, such as hsp90 inhibitors. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: http://www.introgen.com .


Contact:
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
Email: c.burke@introgen.com

Tara Minerals not Tara Gold issuing the PP. So the way I read it, TRGD will not have any dilution. TRGD will get paid when Tara Minerals is spun off.

Test EOM

Nickel January 04,11:43
Bid/Ask 15.7026 - 15.7253
Change +0.5594 +3.69%
Low/High 14.9391 - 15.8160

DigiTech re TGB

Nothing filed on Sedar yet.
http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00003212

Per their news release, they will report sometime after market close today.

VANCOUVER, BRITISH COLUMBIA, Dec 13, 2006 (MARKET WIRE via COMTEX) -- Taseko Mines Limited ("Taseko" or the "Company") (TGB, Trade ), a mining exploration, development and production company, will release its fourth quarter and annual earnings results on Monday, December 18, 2006 after market close and will host a conference call on Tuesday, December 19, 2006 at 11:00 AM Eastern Time (8:00 AM Pacific Time) to discuss these results. The conference call may be accessed by dialing (866)831-6270 in Canada and the United States, or (617)213-8858 internationally, using the passcode 46916913. A live and archived audio webcast will also be available at www.tasekomines.com in the Corporate Events section of the Investor Centre.

Liberty Mines Inc.: High Grade Nickel Mineralization Intersected at the Redstone Mine

Timmins, Ontario CANADA, Dec 14, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Liberty Mines Inc. (LBE - TSX Venture), ("Liberty or the Corporation") is pleased to announce that underground drilling at the Redstone Mine has intersected high grade nickel ("Ni") mineralization in the first set of diamond drill cores to test the mineralization to the 1100 foot (335m) level. This round of drilling is part of the ongoing program in the mine to establish an NI 43-101 reserve to the 1500 foot (457m) level in the mine. Most of the drilling was from the drill drift established at the 700 foot (213m) level. The bore holes in this report and some additional drilling will be combined with the scrutinized historical drill data to confirm and extend the historical resource to the 1100 foot level. The vertical depth in the table is the vertical depth below surface that the borehole intercepted the top of the mineralized zone.

Highlights of the results to date

-***-

------------------------------------------------------------------------ -------- Borehole Vertical Depth (m) Intercept (m) Ni % Including ------------------------------------------------------------------------ -------- R06-06 4.22 3.32 18.3% Ni over 0.62m and 252 4.33% Ni over 0.55m ------------------------------------------------------------------------ -------- R06-07 260 0.57 1.43 ------------------------------------------------------------------------ -------- R06-08 257 2.45 3.06 13.7% Ni over 0.35m ------------------------------------------------------------------------ -------- R06-09 265 1.4 5.08 18.45% Ni over 0.35m ------------------------------------------------------------------------ -------- R06-18 355 3.5 1.92 ------------------------------------------------------------------------ -------- R06-19 268 1.5 2.19 ------------------------------------------------------------------------ -------- AND 1.0 3.83 ------------------------------------------------------------------------ -------- R06-20 265 5.9 0.97 ------------------------------------------------------------------------ -------- R06-29 293 10.21 1.2 12.65% Ni over 0.81m ------------------------------------------------------------------------ -------- R06-35 255 2.04 1.74 ------------------------------------------------------------------------ --------

Borehole Coordinates

---------------------------------------------------------- Borehole Easting Northing Azimuth Dip ---------------------------------------------------------- R06-06 3373 3348 292 -23 ---------------------------------------------------------- R06-07 3373 3348 310 -38 ---------------------------------------------------------- R06-08 3373 3348 328 -36 ---------------------------------------------------------- R06-09 3373 3348 19.5 -49 ---------------------------------------------------------- R06-18 3373 3348 7.2 -57 ---------------------------------------------------------- R06-19 3409 3246 350 -66.5 ---------------------------------------------------------- R06-20 3373 3348 318.5 -53.5 ---------------------------------------------------------- R06-29 3373 3348 53.5 -69.5 ---------------------------------------------------------- R06-35 3373 3348 357 -38 ----------------------------------------------------------

-****-

These results demonstrate the rich nickel veins in the komatiite where it contacts the footwall dacite in the intercepted sections of the Redstone Mine.

Drill results will be forthcoming as they become available from the lab, which is currently very back-logged. The next set of results will involve extended zones to the west and to the 1400 foot (427m) level.

The underground electric diamond drilling program is the basis for a reserve calculation to be completed by Mr. Glen Cole MSc (Geo) MSc (Eng) B.Com of SRK Consulting, who is the Qualified Person for the reserve determination as defined by National Instrument 43-101.

About Liberty Mines Inc.

Liberty Mines Inc. is a mineral exploration and development company with a focus on the development and mining of nickel, cobalt, copper and platinum group metals from its properties in Ontario.

CAUTIONARY STATEMENT

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This News Release includes certain "forward looking statements". All statements other than statements of historical fact included in this release, without limitation, statements regarding potential mineralization and reserves, exploration results, and future plans and objectives of Liberty, are forward looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Liberty's expectations are exploration risks, commodity prices, assumed startup and operating costs detailed herein and from time to time in the filings made by Liberty with securities regulators.

Source: Liberty Mines Inc. (TSX-V: LBE) http://www.libertymineral.com

CONTACT: Dr. Gary Nash, PhD (Physics), President & CEO Liberty Mines Inc. Tel: +1 416 238 9736 Fax: +1 780 437 7898 e-mail: gnash@libertymines.com Maximum News Dissemination by Filing Services Canada Inc. Tel: +1 403 717 3898 Fax: +1 403 717 3896 WWW: http://www.usetdas.com

New Director Joins Taseko Board

--------------------------------------------------------------------------------

August 2, 2006, Vancouver, BC - Taseko Mines Limited (TSX: TKO; AMEX: TGB) ("Taseko" or the "Company") has appointed William P. Armstrong, P.Eng., to the Company's Board of Directors.

Mr. Armstrong is a geological engineer with Bachelors and Masters of Applied Science degrees from the University of British Columbia and over 40 years of experience in the exploration and evaluation of base and precious metals projects. He recently retired from Teck Cominco Ltd., where he held the position of General Manager, Resource Evaluation. In that role he was responsible for compilation and review of all mineral reserves and resources for Teck Cominco and, prior to that, Cominco Ltd. Throughout his career, he was actively involved in numerous feasibility studies that brought many new mines into production, notably the Highland Valley Copper and Polaris operations in Canada and the Quebrada Blanca mine in Chile.

His broad range of experience with late stage and producing projects will be invaluable to Taseko as the Company advances with its plans for growth, including the expansion of Gibraltar and the potential development of Prosperity, and the evaluation of new projects that offer the opportunity for near term production.

For further details on Taseko and its properties, please visit the Company's website at www.tasekomines.com or contact Investor Services at (604) 684-6365 or within North America at 1-800-667-2114.

Russell E. Hallbauer
President and CEO

BW - Re SEDAR filings.

I had the same problem finding the new SEDAR filings (frustrating). I found that they can be accessed easily at http://www.stockwatch.com .

HudBay Minerals Inc. (From Sedar Interim Financials)
Consolidated Statement of Earnings
(In thousands of Canadian dollars, except share and per share amounts)
Three months ended
March 31
2006 2005
(Unaudited)
Revenue $ 207,963 $ 151,525
Expenses:
Operating 121,887 117,713
General and administrative 5,928 3,641
Depreciation and amortization 15,542 12,724
Accretion of asset retirement obligation 660 652
Exploration 3,134 569
Foreign exchange (gain) (1,268) (250)
145,883 135,049
Operating earnings 62,080 16,476
Interest expense (4,754) (5,653)
Foreign exchange (loss) on long term debt (824) (1,330)
Gain on derivative instruments (note 10) 4,331 2,364
Interest and other income 1,172 470
Amortization of deferred financing fees (362) (341)
Earnings before income tax 61,643 11,986
Tax recovery (expense) (note 8) 14,343 (2,805)
Earnings for the period $ 75,986 $ 9,181
Earnings per share:
Basic $ 0.89 $ 0.12
Diluted $ 0.70 $ 0.12
Weighted average number of common shares outstanding
Basic 85,392,988 78,547,993
Diluted 108,179,593 79,202,545
See accompanying notes to consolidated financial statements.

Estimate for profit and forward share value based on current price of copper at +$3.70/lb.

From profit figures from below (previous quarter ending 12/31/05) based on copper selling at an average of $1.88/lb they made $0.06/share.

Simply take $3.70/lb - $1.88/lb = $1.82/lb
$1.82/lb x 15.5Mil lbs quarterly production = $28.21Mil
$28.21Mil / 110Mil shares = $0.256/share/quarter
Add the $0.06 to $0.256 = $0.316

Using this simple method "should" take into account all of their expenses based on the quarter ending 12/31/06.

Forward "share value"
$0.316x4 = $1.264 x PE8 = $10.11
$0.316x4 = $1.264 x PE12 = $15.17

This does not take into account several other variables increasing profits which will go into effect later in the year.
-----------------------------------------
(From earnings statement for quarter ending 12/31/05)
Taseko had after tax earnings of $6.7 million, or $0.06 per share ($0.06 per share fully diluted) in the first quarter of its 2006 fiscal year. The Company had an operating profit of $8.1 million for the period.

The Gibraltar mine met its copper production forecast for the quarter and exceeded its molybdenum production forecast by 11%. In addition:

- Revenues of $36.2 million and $5.1 million were realized from sales of copper and molybdenum.

- The average prices realized for sales were US$1.88 per pound for copper and US$22.45 per pound for molybdenum.

- Copper production was 13.4 million pounds in concentrate.

- Copper sales were 16.4 million pounds in 28,912 wet metric tonnes ("WMT") of concentrate.

Anybody done the math on the value of a penny?

160 pennies = one pound

Current penny has a composition of 97.5% zinc
and 2.5% copper

.975 x $1.55/lb = $1.51 + .025 x $3.10/lb = $0.08

Metal value of one pound of pennies = $1.63

Or you could also say it cost our government $1.63 for the metal to make $1.60 worth of pennies...

All IMO only...

Taseko to Re-Start SX-EW Plant at Gibraltar
Thursday April 13, 8:00 am ET


VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Apr 13, 2006 -- Taseko Mines Limited (Vancouver:TKO.V - News)(AMEX:TGB - News) announces that it will begin immediate refurbishment of the solvent extraction and electrowinning (SX-EW) plant at its Gibraltar mine, located near the City of Williams Lake, British Columbia. The anticipated capital cost of rehabilitation of the SX-EW plant is $3 million, with the plant expected to be operational by the fall of 2006.


Gibraltar's SX-EW plant is capable of producing up to 7 million lbs of LME Grade Cathode Copper per year. During its 12 year operation between 1986 and being put on standby in 1998, the plant produced 85 million lbs of Cathode Copper at a cost of approximately US$0.75 per pound.

Over the last fifteen months since the Gibraltar mine re-opened, oxidized copper ore has been removed and stockpiled, while sulphide mineralization has been treated through conventional processes in the mine concentrator. Mining in the Pollyanna Pit has now progressed to the point where sufficient oxidized copper ore is available for placement on the leach pads which can now support continual operation of the SX-EW plant.

Gibraltar has 16.5 million tons of proven and probable oxide reserves in the Pollyanna and Connector Pits grading 0.148% Acid Soluble Cu at a 0.10% cut-off at $1.10 US/lb, as described in the March 2005 technical report by J. Hendry, P.Eng., and S. Wallis, P.Geo., of Roscoe Postle Associates Inc. These reserves contain approximately 23 million lbs of recoverable copper.

In addition to the above stated oxide reserves, a new oxide zone was discovered when the mine was on care and maintenance in 2003. Significant drilling has been completed in this area. Further geological work and engineering will be undertaken between now and the summer of 2006 with plans to develop access and infrastructure to support mining of this new oxide zone, in conjunction with the oxide ore coming from the Pollyanna and Connector Pits.

For further details on Taseko and its properties, please visit the Company's website at www.tasekomines.com or contact Investor Services at (604) 684-6365 or within North America at 1-800-667-2114.

Russell Hallbauer, President and CEO

Yes, nice close. Another small step towards the real value of this stock with current copper prices and the upcoming upgrades.

Taseko Board Approves Upgrade of Concentrator at the Gibraltar Mine

March 30, 2006 14:24:01 (ET)


VANCOUVER, British Columbia, Mar 30, 2006 (BUSINESS WIRE) -- Taseko Mines Limited (TGB, Trade) announces that its Board of Directors has approved a capital expenditure to expand and upgrade the concentrator facility at the Company's Gibraltar Mine, located near the City of Williams Lake in south-central British Columbia. The mine is operated under an agreement between Taseko's wholly owned subsidiary, Gibraltar Mines Ltd., and Ledcor CMI Ltd. This upgrade and expansion project will increase the production capacity of the Gibraltar mine from 70 million pounds to 100 million pounds of copper per year by 2008.

The approved $62 million dollar expenditure will expand the concentrator's grinding circuit by incorporating a Semi Autogenous Grinding (SAG) mill that will improve the efficiency of the present milling and crushing system. The project also includes a complete replacement of the flotation recovery system. The expanded milling capacity and upgraded flotation system will decrease Gibraltar's unit operating costs by roughly 10% through a combination of increased throughput and improved recoveries of both copper and molybdenum.

The ore processing capacity of the mill will increase by 25%, from the current 36,750 tons per day to 46,000 tons per day. As a result of the increased capacity and the improved recoveries related to the new flotation system, the annual copper production is expected to rise by 30% to approximately 100 million pounds per year. The new SAG mill will, however, be capable of processing up to 50,000 tons of ore per day, depending on ore characteristics and operating strategy. Additional engineering analyses of the tailings system and electrical infrastructure, as well as long-term mine plans, are being undertaken to determine whether that additional daily throughput can be achieved.

President and CEO Russell Hallbauer said: "This expansion is a major step towards the long-term viability of the Gibraltar mine. The expansion is being undertaken at less than one-half the cost of the typical new greenfield construction projects that are under consideration by other mid-tier mining companies, plus it will provide a major increase in copper production in a much shorter time frame compared to greenfield projects. As an added bonus, the project at Gibraltar can be completed with no interruption of current copper and molybdenum production."

Funding for the expansion will come from a combination of internally generated cash flows and commercial capital sources. The upgrade to the flotation system will begin immediately. Construction of the grinding circuit will begin in the summer of 2006, with completion planned for the latter part of 2007.

For further details on Taseko Mines Limited, please contact Investor Services at (604) 684-6365 or within North America at 1-800-667-2114.

Russell Hallbauer, President and CEO

Board is under Taseko's old symbol so not easy to locate EOM